stoxline Quote Chart Rank Option Currency Glossary
  
ARS Pharmaceuticals, Inc. (SPRY)
13.29  -0.15 (-1.12%)    05-12 16:00
Open: 13.21
High: 13.655
Volume: 1,920,929
  
Pre. Close: 13.44
Low: 12.96
Market Cap: 1,305(M)
Technical analysis
2025-05-12 4:52:10 PM
Short term     
Mid term     
Targets 6-month :  16.4 1-year :  18.03
Resists First :  14.04 Second :  15.43
Pivot price 14.02
Supports First :  11.8 Second :  9.81
MAs MA(5) :  13.54 MA(20) :  14.19
MA(100) :  12.46 MA(250) :  12.28
MACD MACD :  0 Signal :  0.2
%K %D K(14,3) :  15.7 D(3) :  17.9
RSI RSI(14): 45.1
52-week High :  18.51 Low :  7.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SPRY ] has closed above bottom band by 10.4%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 13.68 - 13.76 13.76 - 13.84
Low: 12.75 - 12.83 12.83 - 12.92
Close: 13.13 - 13.28 13.28 - 13.44
Company Description

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Headline News

Wed, 07 May 2025
ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx Website - marketscreener.com

Wed, 07 May 2025
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to - Stock Titan

Wed, 07 May 2025
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to - Yahoo Finance

Mon, 05 May 2025
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results - GlobeNewswire

Mon, 05 May 2025
ARS Pharmaceuticals Sets Q1 2025 Earnings Date: Key Updates Expected on Anaphylaxis Treatment Progress - Stock Titan

Fri, 02 May 2025
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 98 (M)
Shares Float 47 (M)
Held by Insiders 21.1 (%)
Held by Institutions 76.1 (%)
Shares Short 16,730 (K)
Shares Short P.Month 17,150 (K)
Stock Financials
EPS 0.07
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.61
Profit Margin 8.9 %
Operating Margin 54.5 %
Return on Assets (ttm) -0.7 %
Return on Equity (ttm) 3.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0.69
Sales Per Share 0.9
EBITDA (p.s.) -0.04
Qtrly Earnings Growth 0 %
Operating Cash Flow 14 (M)
Levered Free Cash Flow 9 (M)
Stock Valuations
PE Ratio 166.12
PEG Ratio 0
Price to Book value 5.07
Price to Sales 14.64
Price to Cash Flow 96.32
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android